Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab +/- BCG in High-Risk NMIBC
NCT02792192Phase 2Terminated
- Sponsor
- Roche
- Start
- Jun 2016
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Roche. Started Jun 2016; status: terminated.
02
Drugs
atezolizumab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02792192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792192.